Numerically, the CKD-EPI equation employing both creatinine and cystatin C had the highest correlation for trough dabigatran concentrations. In the setting of a drug for which there is no currently validated method for monitoring its clinical efficacy, it is useful to know that all of the tested renal function equations have a similar capacity to guide adjustment of dabigatran etexilate dose rates.
Further research to determine the impact of each GFR equation on dabigatran dosing requirements using simulations from a non-linear mixed model is underway. Acknowledgments We would like to thank Stephanie Rose, Amjad Hamid, Amr BinSadiq and Lorraine Skelton (Christchurch selleck kinase inhibitor Hospital) for assistance with patient recruitment; Mark Lewis (Canterbury Health Laboratories)
for assistance with the dabigatran assay; Lesney Stuart and the staff at Core find more Biochemistry (Canterbury Health Laboratories) for the creatinine and thyroid-related assays; Charles Hawes (Canterbury Health Laboratories) for the cystatin C assays; and Chris Frampton for advice with the statistical analyses. Paul K. L. Chin is a recipient of the Health Research Council of New Zealand Clinical Research Training Fellowship (2012–2014). Open AccessThis article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the
OICR-9429 purchase source are credited. Cell Penetrating Peptide Electronic Supplementary Material Below is the link to the electronic supplementary material. Supplementary material 1 (DOCX 83 kb) References 1. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719–47. doi:10.1093/eurheartj/ehs253.PubMedCrossRef 2. Skanes AC, Healey JS, Cairns JA, Dorian P, Gillis AM, McMurtry MS, et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol. 2012;28(2):125–36. doi:10.1016/j.cjca.2012.01.021.PubMedCrossRef 3. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e44S–88S. doi:10.1378/chest.11-2292.PubMedPubMedCentral 4. Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, et al.